.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.

Prof. Oliver A. Cornely

Cologne/ DE

Vortrag

26.09.2023
12:35 – 13:00 20 Min. 5 Min.
Corona vaccination in advanced age BUT what else did we find in runny noses

Weitere Beteiligungen

25.09.2023
Poster
P-1-42
Improved clinical outcome of Covid-19 in haematologic malignancy patients receiving a fourth dose of anti-SARS-Cov-2 vaccine: an epicovideha report
Immune Prevention and Therapy
25.09.2023
Poster
P-1-43
Molnupiravir compared to nirmatrelvir/ritonavir for Covid-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the epicovideha registry
Immune Prevention and Therapy
25.09.2023
Poster
P-1-44
Nirmatrelvir/ritonavir in Covid-19 patients with haematological malignancies: a report from the epicovideha registry
Immune Prevention and Therapy
25.09.2023
Poster
P-1-45
Pre-exposure immunization by tixagevimab/cilgavimab in hematological malignancy and Covid-19 in the epicovideha registry
Immune Prevention and Therapy
25.09.2023
Poster
P-1-46
The current state of laboratory mycology in Asia/Pacific: a survey from the European Confederation of Medical Mycology (ECMM) and International Society for Human and Animal Mycology (ISHAM)
Immune Prevention and Therapy
25.09.2023
Poster
P-1-47
Laboratory capacities to diagnose and treat invasive fungal infections in Europe: results from the ECMM survey
Immune Prevention and Therapy
25.09.2023
Poster
P-1-48
Immunogenicity and reactogenicity of a first booster with BNT162B2 or full-dose of MRNA-1273: a randomised trial in adults ≥75 years (EU-COVAT-1) from the vaccelerate consortium
Immune Prevention and Therapy
25.09.2023
Poster
P-1-49
Multipathogen antigen test kit (MAK-5) - distribution and frequency of viral respiratory diseases in Germany among volunteers in the vaccelerate registry
Immune Prevention and Therapy
25.09.2023
Poster
P-1-50
Poliovirus vaccination status among adult participants in the vaccelerate volunteer registry
Immune Prevention and Therapy
25.09.2023
Poster
P-1-51
Establishing the vaccelerate site network: capacity mapping of clinical trial sites
Immune Prevention and Therapy
25.09.2023
Poster
P-1-52
The first two years of the European vaccelerate volunteer registry
Immune Prevention and Therapy
25.09.2023
Poster
P-1-53
Country-specific needs, ethics and regulatory requisites related to implementing a trial volunteer registry across Europe: the vaccelerate volunteer registry experience
Immune Prevention and Therapy
25.09.2023
Poster
P-1-54
The Argentinian Landscape of mycological diagnostic capacity and treatment
Immune Prevention and Therapy
25.09.2023
Poster
P-1-55
Laboratory capacities to diagnose and treat invasive fungal infections in Austria, Germany and Switzerland
Immune Prevention and Therapy
25.09.2023
Poster
P-1-56
Laboratory capacities to diagnose and treat invasive fungal infections in Italy: local results from an ECMM survey
Immune Prevention and Therapy
25.09.2023
Poster
P-1-57
Laboratory capacities to diagnose and treat invasive fungal infections in Nordic countries: results from an NSMM and ECMM survey
Immune Prevention and Therapy
25.09.2023
Poster
P-1-68
Duration of protection from pneumonia after pneumococcal vaccination in haemodialysis patients – interim analysis of the DOPPIO study
Immune Prevention and Therapy
26.09.2023
Poster
P-2-1
Public health communication for vaccine trials: the VACCELERATE pan-European toolkit
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
26.09.2023
Poster
P-2-2
Research nurses in Europe: education paths and key tasks. Results from VACCELERATE
Data Science and Bioresources
26.09.2023
Poster
P-2-17
Epidemiology of fungal drug resistance in Germany
Antimicrobial Resistance
26.09.2023
15:05 – 15:20 10 Min. 5 Min.
Highlight-Vortrag
S-6-2
Multipathogen Antigen Test Kit (MAK-5) – distribution and frequency of viral respiratory diseases in Germany among volunteers in the VACCELERATE Registry
Tropical and Emerging Infections